CAFs represent a major component of the TME and suppress the infiltration of CD8+ T cells into the tumor site in breast cancer; targeting CAF subsets via genetic deletion facilitates CD8+ T-cell infiltration and enhances sensitivity to immunotherapy [42], further enhancing clinical outcomes [43]. Here, CD8A is linked to breast cancer.